Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
| # | Name | Date |
|---|---|---|
| 1 | 202347076827-STATEMENT OF UNDERTAKING (FORM 3) [10-11-2023(online)].pdf | 2023-11-10 |
| 2 | 202347076827-Sequence Listing in txt [10-11-2023(online)].txt | 2023-11-10 |
| 3 | 202347076827-Sequence Listing in PDF [10-11-2023(online)].pdf | 2023-11-10 |
| 4 | 202347076827-PRIORITY DOCUMENTS [10-11-2023(online)].pdf | 2023-11-10 |
| 5 | 202347076827-POWER OF AUTHORITY [10-11-2023(online)].pdf | 2023-11-10 |
| 6 | 202347076827-FORM 18 [10-11-2023(online)].pdf | 2023-11-10 |
| 7 | 202347076827-FORM 1 [10-11-2023(online)].pdf | 2023-11-10 |
| 8 | 202347076827-FIGURE OF ABSTRACT [10-11-2023(online)].pdf | 2023-11-10 |
| 9 | 202347076827-DRAWINGS [10-11-2023(online)].pdf | 2023-11-10 |
| 10 | 202347076827-DECLARATION OF INVENTORSHIP (FORM 5) [10-11-2023(online)].pdf | 2023-11-10 |
| 11 | 202347076827-COMPLETE SPECIFICATION [10-11-2023(online)].pdf | 2023-11-10 |
| 12 | 202347076827-Proof of Right [15-03-2024(online)].pdf | 2024-03-15 |
| 13 | 202347076827-RELEVANT DOCUMENTS [29-07-2025(online)].pdf | 2025-07-29 |